All of these agents share the same core pharmacology: they mimic the gut hormone GLP1, which signals satiety, slows gastric emptying, and enhances insulin secretion, leading to reduced appetite and significant, sustained weight loss
Its challenge is that glucagon receptor activity adds another pharmacologic dimension to monitor
Offer alternative treatment plans When FDA-approved GLP-1s arent accessible, consider: Non-GLP-1 pharmacologic options: Bupropion-naltrexone ER (Contrave ) Phentermine-topiramate ER (Qsymia ) Orlistat Lifestyle-based programs: Structured weight management programs
Q: Can AI really be trusted to identify drug side effects from social media posts
We conducted a randomized, double-blind, placebo-controlled multiple ascending dose phase 1 study at a single center in the Republic of Korea in adults with overweight (BMI 2530 kg/m)
Obesity and metabolic dysfunction can disrupt the normal progression through these stages, reducing time spent in the most restorative phases